Web based Drug Database (1.07 Linux)

KETOROLAC TROMETAMOL

Names
Common Name	KETOROLAC TROMETAMOL
Other Name	KETOROLAC TROMETAMOL
Pharmacological Group	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Name	(+/-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Postoperative pain

Contraindications

Asthma
Peptic ulcer
GIT haemorrhage
Analgesic allergy
Dehydrated
Nasal polyps
Hypovolaemia
Dehydration
Subarachnoid haemorrhage
Intracerebral haemorrhage
Other and unspecified intracranial haemorrhage
Nasal polyp
Chronic asthmatic bronchitis
Gastric ulcer
Duodenal ulcer
Peptic ulcer - (PU) site unspecified
Gastrojejunal ulcer
Gastritis and duodenitis
Salicylate poisoning
Accidental poisoning by salicylates
Adverse reaction to salicylates
Adverse reaction to antirheumatics
Airways obstruction reversible
Non-steroidal anti-inflammatory drugs contraindicated

Prescriber Cautions

Consult current official advice regarding KETOROLAC TROMETAMOL

Patient Cautions

See information on products containing KETOROLAC TROMETAMOL for specific advice for patients

Toxicity

- None Listed -

Side Effects

Abdominal discomfort
Abdominal pain
Abnormal weight gain
Acute gastritis
Acute hepatic failure
Acute hepatitis
Acute pancreatitis
Agranulocytosis
Allergic purpura
Anxiousness
Aplastic anaemia
Black faeces
Bleeding time increased
Blood in urine - haematuria
Blood urea raised
Bradycardia
Bronchospasm
Chemical oesophagitis
Chest pain
Constipation
Convulsions
Depression
Diarrhoea
Dizziness
Dreams
Drowsiness
Drug psychoses
Dry mouth
Dyspepsia
Dyspnoea
Epistaxis
Euphoria
Excessive eructation
Excessive flatulence
Excessive sweating
Excessive thirst
Exfoliative dermatitis
Fatigue/asthenia
Flushing
Frequency of micturition
Gastrointestinal haemorrhage
Haematemesis
Haemolytic anaemia
Haemorrhage of rectum and anus
Hallucinations
Headache
Hearing difficulty
Heart failure
Hyperkalaemia
Hyperkinesia
Hypertension
Hyposmolality/hyponatraemia
Hypotension
Infertility - female
Insomnia
Interstitial nephritis
Itching
Jaundice
Laryngeal oedema
Liver function tests abnormal
Macules
Malaise/lethargy
Meningitis - aseptic
Myalgia
Nausea
Nephrotic syndrome
Nervousness
Neutropenia
Oedema
Oliguria
Optic neuritis
Oral aphthae
Pain at injection site
Pallor
Palpitations
Papules
Paraesthesia
Peptic ulcer symptoms
Perforation of intestine
Photosensitiveness
Poor concentration
Pulmonary oedema
Pyrexia
Rash
Renal function tests abnormal
Serum creatinine abnormal
Spontaneous bruising
Stevens-Johnson syndrome
Taste disturbance
Thrombocytopenia
Toxic epidermal necrolysis
Urinary retention
Visual symptoms
Vomiting

Liver Disease

Avoid KETOROLAC TROMETAMOL in severe liver disease
KETOROLAC TROMETAMOL causes sodium and water retention in liver disease
KETOROLAC TROMETAMOL - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Manufacturer advises reduce dose of KETOROLAC TROMETAMOL in renal failure
Monitor serum creatinine

Pregnancy

With regular doses of KETOROLAC TROMETAMOL - increased risk of closure of fetal ductus arteriosus in utero & possible persistent pulmonary hypertension of the newborn
Delayed onset & increased duration of labour with increased blood loss
Manufacturer advises toxicity of KETOROLAC TROMETAMOL in pregnancy in animal studies
Avoid KETOROLAC TROMETAMOL in the 1st, 2nd & 3rd TRIMESTER of pregnancy

Lactation

Manufacturer advises avoid KETOROLAC TROMETAMOL in breast feeding
Amount of KETOROLAC TROMETAMOL in breast milk probably too small to be harmful

Pharmacological Actions

ANALGESIC effect
ANTIINFLAMMATORY effect
ANTIPYRETIC effect
CYCLOOXYGENASE INHIBITOR effect

Diagnostic Procedures

- None Listed -

Drugs containing KETOROLAC TROMETAMOL

KETOROLAC 30mg/1mL i-m inj
TORADOL 30mg/1mL i-m inj
KETOROLAC TROMETAMOL 10mg tabs
TORADOL 10mg tablets
KETOROLAC TROMET 10mg/1mL inj
TORADOL 10mg/1mL injection

Interacting Ingredients

ACECLOFENAC
Likely interaction of ACECLOFENAC increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
ACEMETACIN
Likely interaction of ACEMETACIN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
ACENOCOUMAROL
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of ACENOCOUMAROL. High risk. May need to avoid combination
ALOXIPRIN
Likely interaction of ALOXIPRIN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
AMINOPHYLLINE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of AMINOPHYLLINE. High risk. May need to avoid combination
ASPIRIN
Likely interaction of ASPIRIN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
ASPIRIN [RECTUM]
Likely interaction of ASPIRIN [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
AZAPROPAZONE
Likely interaction of AZAPROPAZONE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
BAMBUTEROL HYDROCHLORIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. High risk. May need to avoid combination
BECLOMETASONE [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. High risk. May need to avoid combination
BENORILATE
Likely interaction of BENORILATE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
BETAMETHASONE [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. High risk. May need to avoid combination
BISMUTH CHELATE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of BISMUTH CHELATE. High risk. May need to avoid combination
BUDESONIDE [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. High risk. May need to avoid combination
BUFYLLINE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of BUFYLLINE. High risk. May need to avoid combination
BUMETANIDE
Theoretical potential for KETOROLAC TROMETAMOL reducing the DIURETIC effect of BUMETANIDE. Moderate risk. Monitor
BUPRENORPHINE
Infrequent reports of KETOROLAC TROMETAMOL increasing the RESPIRATORY DEPRESSANT effect of BUPRENORPHINE. Usually no risk. Usually no action necessary
CANDESARTAN CILEXETIL
Likely interaction of KETOROLAC TROMETAMOL increasing the NEPHROTOXICITY of CANDESARTAN CILEXETIL. Potential risk. Monitor
CAPTOPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of CAPTOPRIL. Potential risk. Avoid
CARBENOXOLONE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of CARBENOXOLONE. High risk. May need to avoid combination
CELECOXIB
Likely interaction of CELECOXIB increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
CHOLINE MAGNESIUM TRISALICYLATE
Likely interaction of CHOLINE MAGNESIUM TRISALICYLATE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
CHOLINE THEOPHYLLINATE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. High risk. May need to avoid combination
CILAZAPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of CILAZAPRIL. Potential risk. Avoid
CIMETIDINE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of CIMETIDINE. High risk. May need to avoid combination
CROMOGLICATE [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. High risk. May need to avoid combination
DANAPAROID SODIUM
Theoretical potential for KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of DANAPAROID SODIUM. Moderate risk. May need to avoid combination
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of DEGLYCYRRHIZINISED LIQUORICE. High risk. May need to avoid combination
DEXIBUPROFEN
Likely interaction of DEXIBUPROFEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
DEXKETOPROFEN
Likely interaction of DEXKETOPROFEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
DICLOFENAC POTASSIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
DICLOFENAC SODIUM [ORAL]
Likely interaction of DICLOFENAC SODIUM [ORAL] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
DICLOFENAC SODIUM [PARENTERAL]
Likely interaction of DICLOFENAC SODIUM [PARENTERAL] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
DICLOFENAC SODIUM [RECTUM]
Likely interaction of DICLOFENAC SODIUM [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
DIFLUNISAL
Likely interaction of DIFLUNISAL increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
DIPROPHYLLINE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of DIPROPHYLLINE. High risk. May need to avoid combination
ENALAPRIL MALEATE
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of ENALAPRIL MALEATE. Potential risk. Avoid
ENOXAPARIN
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of ENOXAPARIN. Moderate risk. May need to avoid combination
EPHEDRINE HYDROCHLORIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. High risk. May need to avoid combination
EPROSARTAN
Likely interaction of KETOROLAC TROMETAMOL increasing the NEPHROTOXICITY of EPROSARTAN. Potential risk. Monitor
ESOMEPRAZOLE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of ESOMEPRAZOLE. High risk. May need to avoid combination
ETODOLAC
Likely interaction of ETODOLAC increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
ETORICOXIB
Likely interaction of ETORICOXIB increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
FAMOTIDINE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of FAMOTIDINE. High risk. May need to avoid combination
FENBUFEN
Likely interaction of FENBUFEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
FENOPROFEN
Likely interaction of FENOPROFEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
FENOTEROL HYDROBROMIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. High risk. May need to avoid combination
FLURBIPROFEN
Likely interaction of FLURBIPROFEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
FLURBIPROFEN [RECTUM]
Likely interaction of FLURBIPROFEN [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
FLUTICASONE [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. High risk. May need to avoid combination
FONDAPARINUX SODIUM
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of FONDAPARINUX SODIUM. Moderate risk. May need to avoid combination
FORMOTEROL
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of FORMOTEROL. High risk. May need to avoid combination
FUROSEMIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the DIURETIC effect of FUROSEMIDE. Moderate risk. May need to avoid combination
HEPARIN
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of HEPARIN. High risk. May need to avoid combination
HEPARIN [EXCIPIENT]
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of HEPARIN [EXCIPIENT]. High risk. May need to avoid combination
IBUPROFEN
Likely interaction of IBUPROFEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
IBUPROFEN LYSINE
Likely interaction of IBUPROFEN LYSINE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
INDACATEROL
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of INDACATEROL. High risk. May need to avoid combination
INDOMETACIN
Likely interaction of INDOMETACIN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
INDOMETACIN [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
IRBESARTAN
Likely interaction of KETOROLAC TROMETAMOL increasing the NEPHROTOXICITY of IRBESARTAN. Potential risk. Monitor
ISOETARINE HYDROCHLORIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. High risk. May need to avoid combination
ISOPRENALINE HYDROCHLORIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. High risk. May need to avoid combination
ISOPRENALINE SULPHATE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. High risk. May need to avoid combination
KETOPROFEN
Likely interaction of KETOPROFEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOPROFEN [RECTUM]
Likely interaction of KETOPROFEN [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOTIFEN
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of KETOTIFEN. High risk. May need to avoid combination
LANSOPRAZOLE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of LANSOPRAZOLE. High risk. May need to avoid combination
LISINOPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of LISINOPRIL. Potential risk. Avoid
LOSARTAN POTASSIUM
Likely interaction of KETOROLAC TROMETAMOL increasing the NEPHROTOXICITY of LOSARTAN POTASSIUM. Potential risk. Monitor
LUMIRACOXIB
Likely interaction of LUMIRACOXIB increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
LYSINE ASPIRIN
Likely interaction of LYSINE ASPIRIN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
MEFENAMIC ACID
Likely interaction of MEFENAMIC ACID increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
MELOXICAM
Likely interaction of MELOXICAM increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
MELOXICAM [RECTUM]
Likely interaction of MELOXICAM [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
METHYLEPHEDRINE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. High risk. May need to avoid combination
MISOPROSTOL
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of MISOPROSTOL. High risk. May need to avoid combination
MOEXIPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of MOEXIPRIL. Potential risk. Avoid
MONTELUKAST
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of MONTELUKAST. High risk. May need to avoid combination
NABUMETONE
Likely interaction of NABUMETONE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
NAPROXEN
Likely interaction of NAPROXEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
NAPROXEN SODIUM
Likely interaction of NAPROXEN SODIUM increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
NAPROXEN [RECTUM]
Likely interaction of NAPROXEN [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
NEDOCROMIL SODIUM
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. High risk. May need to avoid combination
NIZATIDINE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of NIZATIDINE. High risk. May need to avoid combination
OLMESARTAN MEDOXOMIL
Likely interaction of KETOROLAC TROMETAMOL increasing the NEPHROTOXICITY of OLMESARTAN MEDOXOMIL. Potential risk. Monitor
OMEPRAZOLE [ORAL]
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of OMEPRAZOLE [ORAL]. High risk. May need to avoid combination
OMEPRAZOLE [PARENTERAL]
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of OMEPRAZOLE [PARENTERAL]. High risk. May need to avoid combination
ORCIPRENALINE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of ORCIPRENALINE. High risk. May need to avoid combination
ORCIPRENALINE [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. High risk. May need to avoid combination
PANTOPRAZOLE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of PANTOPRAZOLE. High risk. May need to avoid combination
PARECOXIB SODIUM
Likely interaction of PARECOXIB SODIUM increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
PENTOXIFYLLINE
Likely interaction of PENTOXIFYLLINE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. Potential risk. Avoid
PERINDOPRIL ARGININE
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of PERINDOPRIL ARGININE. Potential risk. Avoid
PERINDOPRIL ERBUMINE
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of PERINDOPRIL ERBUMINE. Potential risk. Avoid
PHENINDIONE
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of PHENINDIONE. High risk. May need to avoid combination
PHENYLBUTAZONE
Likely interaction of PHENYLBUTAZONE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
PIRBUTEROL
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of PIRBUTEROL. High risk. May need to avoid combination
PIROXICAM
Likely interaction of PIROXICAM increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
PIROXICAM-BETADEX
Likely interaction of PIROXICAM-BETADEX increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
PROBENECID
Likely interaction of PROBENECID reducing the ANALGESIC effect of KETOROLAC TROMETAMOL. Potential risk. Avoid
QUINAPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of QUINAPRIL. Potential risk. Avoid
RABEPRAZOLE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of RABEPRAZOLE. High risk. May need to avoid combination
RAMIPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of RAMIPRIL. Potential risk. Avoid
RANITIDINE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of RANITIDINE. High risk. May need to avoid combination
RANITIDINE BISMUTH CITRATE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of RANITIDINE BISMUTH CITRATE. High risk. May need to avoid combination
REPROTEROL HYDROCHLORIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. High risk. May need to avoid combination
RIMITEROL HYDROBROMIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. High risk. May need to avoid combination
RITODRINE HYDROCHLORIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. High risk. May need to avoid combination
ROFECOXIB
Likely interaction of ROFECOXIB increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
SALBUTAMOL
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of SALBUTAMOL. High risk. May need to avoid combination
SALBUTAMOL [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. High risk. May need to avoid combination
SALICYLAMIDE
Likely interaction of SALICYLAMIDE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
SALIX
Likely interaction of SALIX increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
SALMETEROL XINAFOATE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. High risk. May need to avoid combination
SALSALATE
Likely interaction of SALSALATE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
SODIUM FOSINOPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of SODIUM FOSINOPRIL. Potential risk. Avoid
SODIUM SALICYLATE
Likely interaction of SODIUM SALICYLATE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
SUCRALFATE
Likely interaction of KETOROLAC TROMETAMOL increasing the GASTRIC IRRITANT effect of SUCRALFATE. High risk. May need to avoid combination
SULINDAC
Likely interaction of SULINDAC increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
TELMISARTAN
Likely interaction of KETOROLAC TROMETAMOL increasing the NEPHROTOXICITY of TELMISARTAN. Potential risk. Monitor
TENOXICAM
Likely interaction of TENOXICAM increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
TERBUTALINE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of TERBUTALINE. High risk. May need to avoid combination
TERBUTALINE [INHALED]
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. High risk. May need to avoid combination
THEOPHYLLINE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of THEOPHYLLINE. High risk. May need to avoid combination
TIAPROFENIC ACID
Likely interaction of TIAPROFENIC ACID increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
TINZAPARIN SODIUM
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of TINZAPARIN SODIUM. Moderate risk. May need to avoid combination
TOLFENAMIC ACID
Likely interaction of TOLFENAMIC ACID increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
TOLMETIN
Likely interaction of TOLMETIN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
TORASEMIDE
Theoretical potential for KETOROLAC TROMETAMOL reducing the DIURETIC effect of TORASEMIDE. Moderate risk. Monitor
TRANDOLAPRIL
Theoretical potential for KETOROLAC TROMETAMOL increasing the ACE INHIBITOR effect of TRANDOLAPRIL. Potential risk. Avoid
TULOBUTEROL HYDROCHLORIDE
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. High risk. May need to avoid combination
VALDECOXIB
Likely interaction of VALDECOXIB increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
VALSARTAN
Likely interaction of KETOROLAC TROMETAMOL increasing the NEPHROTOXICITY of VALSARTAN. Potential risk. Monitor
VANCOMYCIN [PARENTERAL]
Infrequent reports of VANCOMYCIN [PARENTERAL] increasing the NEPHROTOXICITY of KETOROLAC TROMETAMOL. Usually no risk. Usually no action necessary
WARFARIN SODIUM
Likely interaction of KETOROLAC TROMETAMOL increasing the ANTICOAGULANT effect of WARFARIN SODIUM. High risk. May need to avoid combination
ZAFIRLUKAST
Likely interaction of KETOROLAC TROMETAMOL reducing the BRONCHODILATOR effect of ZAFIRLUKAST. High risk. May need to avoid combination